Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Function Tests01:25

Pulmonary Function Tests

559
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
559
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

316
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
316
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

559
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
559
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.6K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.8K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.8K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The kinetic parameters of dynamic contrast-enhanced MRI with ultrafast imaging in breast cancer patients receiving neoadjuvant chemotherapy: Prediction of pathologic complete response and correlation with histologic microvessel density.

Medicine·2025
Same author

Sirtuin Proteins and Memory: A Promising Target in Alzheimer's Disease Therapy?

Nutrients·2024
Same author

The utility of ultrafast MRI and conventional DCE-MRI for predicting histologic aggressiveness in patients with breast cancer.

Acta radiologica (Stockholm, Sweden : 1987)·2024
Same author

Effect of Seaweed-Derived Fucoidans from <i>Undaria pinnatifida</i> and <i>Fucus vesiculosus</i> on Coagulant, Proteolytic, and Phospholipase A<sub>2</sub> Activities of Snake <i>Bothrops jararaca</i>, <i>B. jararacussu</i>, and <i>B. neuwiedi</i> Venom.

Toxins·2024
Same author

Artificial intelligence for ultrasound microflow imaging in breast cancer diagnosis.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2024
Same author

Oral Supplementation with Algal Sulphated Polysaccharide in Subjects with Inflammatory Skin Conditions: A Randomised Double-Blind Placebo-Controlled Trial and Baseline Dietary Differences.

Marine drugs·2023

Related Experiment Video

Updated: Nov 23, 2025

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

10.9K

Fucoidan and Lung Function: Value in Viral Infection.

J Helen Fitton1, Ah Young Park1, Samuel S Karpiniec1

  • 1Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, TAS 7170, Australia.

Marine Drugs
|December 30, 2020
PubMed
Summary

Fucoidans may protect against lung damage from viral infections like SARS-CoV-2 by boosting immunity and reducing inflammation. Research explores fucoidan

Keywords:
COPDcoronafibrosisfucoidaninfluenzalungrespiratory

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.3K
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.8K

Related Experiment Videos

Last Updated: Nov 23, 2025

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

10.9K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.3K
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

10.8K

Area of Science:

  • Pulmonology
  • Immunology
  • Virology

Background:

  • Viral infections, including SARS-CoV-2, cause acute and chronic lung damage by suppressing innate immunity and increasing inflammation.
  • Compromised lung function is a common outcome of both infectious and non-infectious diseases.

Purpose of the Study:

  • To review current research on fucoidan's effects on viral lung infections and associated damage.
  • To explore fucoidan's potential as a therapeutic agent against SARS-CoV-2-induced lung injury.

Main Methods:

  • Review of existing clinical and animal studies on fucoidan.
  • Analysis of research on fucoidan's impact on innate immunity and inflammation.
  • Examination of studies investigating fucoidan's role in viral infection models.

Main Results:

  • Fucoidans have demonstrated the ability to enhance innate immunity and reduce inflammation in clinical and animal studies.
  • Dietary fucoidan has shown efficacy in mitigating pulmonary damage during acute viral infections.
  • While some studies show direct inhibition of SARS-CoV-2 in vitro, this effect is not universally observed.

Conclusions:

  • Fucoidans show promise in managing lung damage caused by viral infections, particularly SARS-CoV-2.
  • Targeting innate immunity and inflammation with fucoidan may offer a strategy to combat viral lung pathologies.
  • Further research is warranted to fully elucidate fucoidan's therapeutic potential for viral lung infections.